Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT, Taubenberger JK. · 2016

Read Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model. by Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT, Taubenberger JK. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4959521.txt.

Introduction

Matthew J. Memoli leads a team testing which flu antibodies truly track with protection. Their study appeared in mBio in 2016. Flu vaccines are judged by the HAI titer, a measure of antibodies against hemagglutinin, the virus's main surface protein. A titer of 1:40 or more counts as protective. Recent weak vaccine seasons raised doubts about that single marker. The team used a human challenge model at the NIH Clinical Center, giving healthy volunteers a wild type 2009 H1N1 virus through the nose.

Volunteers starting at or above the threshold were less likely to develop mild to moderate flu disease. The titer did not cut symptoms alone, though. Antibodies against the second surface protein, neuraminidase, tracked better with every severity measure the team checked. The authors argue vaccine testing should weigh neuraminidase antibodies too. Relying on one correlate, they say, can misjudge how well a vaccine will work.

Catalog record

CREATORMemoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT, Taubenberger JK.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4959521

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model By Matthew J. Memoli, Pamela A. Shaw, Alison Han, Lindsay Czajkowski, Susan Reed, Rani Athota, Tyler Bristol, Sarah Fargis, Kyle Risos, John H. Powers, Richard T. Davey, Jeffery K. Taubenberger Published in: mBio DOI: 10.1128/mBio.00417-16 ABSTRACT ABSTRACT Despite long-term investment, influenza continues to be a significant worldwide problem. The cornerstone of protection remains vaccination, and approved vaccines seek to elicit a hemagglutination inhibition (HAI) titer of ≥1:40 as the primary correlate of protection. However, recent poor vaccine performance raises questions regarding the protection afforded and whether other correlates of protection should be targeted. A healthy volunteer challenge study was performed with a wild-type 2009 A(H1N1)pdm influenza A challenge virus at the NIH Clinical Center to evaluate two groups of participants with HAI titers of ≥1:40 and <1:40. The primary objective was to determine whether participants with HAI titers of ≥1:40 were less likely to develop mild to moderate influenza disease (MMID) after intranasal inoculation. HAI titers of ≥1:40 were protective against MMID but did not reduce the incidence of symptoms alone. Although the baseline HAI titer correlated with some reduction in disease severity measures, overall, the baseline NAI titer correlated more significantly with all disease severity metrics and had a stronger independent effect on outcome. This study demonstrates the importance of examining other immunological correlates of protection rather than solely HAI titers. This challenge study confirms the importance of NAI titer as a correlate and for the first time establishes that it can be an independent predictor of reduction of all aspects of influenza disease. This suggests that NAI titer may play a more significant role than previously thought and that neuraminidase immunity should be considered when studying susceptibility after vaccination and as a critical target in future influenza vaccine platforms. INTRODUCTION Despite significant investment in influenza preparedness, annual estimates of death due to seasonal influenza range up to 49,000 in the United States (1) and 250,000 to 500,000 deaths in industrialized countries (2, 3). Pandemics can have an even more devastating effect, and continued efforts are being made to improve countermeasures for this worldwide problem (4). Currently, vaccination is the cornerstone of prophylaxis and the most effective method available to reduce the yearly impact of influenza on the world’s population (5, 6). Influenza vaccines in widespread use are standardized by the amount of the major surface glycoprotein, hemagglutinin (HA), contained in the vaccine preparation. Measurements of serum antibodies in response to the HA are the current gold standard for evaluating vaccines. The U.S. Food and Drug Administration and the European Medicines Agency Committee for Medicinal Products for Human Use both define “protective” titers as a hemagglutination inhibition (HAI) titer of ≥1:40 (7). The evidence for this cutoff comes from a seminal live influenza virus challenge trial conducted in 1972 by Hobson et al., which established that a prechallenge serum HAI titer of 18 to 36 was associated with 50% protection from infection (8), and a similar study demonstrating a 29% infection rate in those with HAI titers of 1:40 to 60 (9). Other studies in the setting of live and attenuated influenza virus challenge have been less conclusive (10–12). A more recent study, conducted using live attenuated viruses, demonstrated 50% protection from intranasal infection in those with titers of ≥1:40 (13), but a recent epidemiological study of vaccine performance has brought this into question, with only 22% protection of children with postvaccination titers of ≥1:40 (14). Even more concerning are data from the recent influenza seasons suggesting that current seasonal vaccines held to these standards are greatly underperforming, as overall seasonal vaccine effectiveness over the past 10 years has ranged from 10 to 56% with a mean of 40% (15). This is especially concerning for at risk populations who most require protection and in whom even worse performance has been observed (16). The variability of results in past studies and variations in recent influenza vaccine efficacy are likely multifactorial and suggest that more work is needed to better understand the correlates of protection in influenza infection. Differences in outcome measures, well described interlaboratory variations in HAI and microneutralization assay results (17, 18), evolving viral phenotypes, host factors, and differences in how protection is defined could all further confound interpretation of results and contribute to the variation seen in these and other studies of influenza immunity. Currently, vaccine efficacy is evaluated predominantly by increases in HAI titers, and other possible correlates of immune protection (e.g., neuraminidase inhibition [NAI] titers or other types of immunity) have generally either not been examined or have been relegated to secondary considerations. This study was designed to evaluate the role of the traditional “protective” HAI titer of ≥1:40 as a correlate of protection in an established well-controlled human challenge study with the influenza A/2009 A(H1N1)pdm (pdm stands for pandemic) virus (19). This is the first healthy volunteer challenge study to specifically evaluate this cutoff since it was established. Virologic and clinical data as correlative parameters of protection were compared between patients with prechallenge titers of ≥1:40 or <1:40. The human challenge model employed in this trial offered a unique opportunity to overcome many of the limitations of past studies and perform not only a comprehensive evaluation of HAI but also to investigate the correlation of antineuraminidase antibodies to protection as measured by baseline neuraminidase inhibition titers. Understanding how these baseline antibody titers predict outcomes as correlates of protection allows us to better understand how different immune factors may interact as independent and dependent factors in influenza disease and may lead to further identification of other correlates of protection, development of better tools to predict outcomes, and identify improved vaccine targets and countermeasures. RESULTS Seventy-four participants were eligible after screening. As the screening took place up to 3 months in advance, some participants were found to have higher or lower titers at the time of admission so they were moved to the appropriate group for analysis (Fig. 1). After enrollment in the study, three participants were found ineligible for safety reasons and were excluded from challenge, and an additional six were subsequently excluded after testing positive for other respiratory infections within 48 h of influenza virus challenge (Fig. 1). Thus, 65 participants challenged were included in this analysis, 25 participants in the high-titer group with an HAI titer of ≥1:40 (geometric mean titer [GMT] of 214.9) and 40 participants in the low-titer group with an HAI titer of <1:40 (GMT of 6.4). There were no significant differences in age, gender, race, or ethnicity between the two HAI titer groups (Table 1). [Figure: Study flow chart. A total of 200 volunteers were screened for participation. Of these volunteers, 74 were enrolled in the study with 40 in the high-HAI-titer group and 34 in the low-HAI-titer group up to 3 months prior to challenge. On admission for challenge, 16 participants were found to have HAI titers that had increased or decreased since the time of screening either due to waning titers or exposure to virus. Three participants were excluded prior to challenge for safety reasons. Thirty-one participants on the high-titer group and 40 participants in the low-titer group were

Read the complete text